Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
The corona virus pandemic may affects patients regular visits to ophthalmic clinic, we aim to study the sequel of the pandemic on intravitreal injections results in diabetic macular edema, wet age related macular degenerations, myopic choroidal new vascularization, and proliferative diabetic retinopathy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diabetic macular edema | Active Comparator | Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors. |
|
| Wet age related macular edema | Active Comparator | Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors. |
|
| Retinal vein occlusion | Active Comparator | Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors. |
|
| Myopic choroidal new vascularization | Active Comparator | Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-vascular endothelial growth factors (Anti-VEGFs) | Drug | Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Visual acuity | Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart. | Baseline and monthly after injection till one year of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Central subfield thickness | Assessing the changes in central macular thickness in microns measured by optical coherence tomography | Baseline and monthly after injection till one year of follow-up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed A Tabl, MD | Contact | 01222328766 | ahmad4lg@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed A Tabl | Benha University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ahmed Abdelshafy Tabl | Recruiting | Banhā | Benha | 13511 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D020256 | Choroidal Neovascularization |
| D003930 | Diabetic Retinopathy |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D015862 | Choroid Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D014603 |
| Uveal Diseases |
| D009389 | Neovascularization, Pathologic |
| D008679 | Metaplasia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |